Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Soubrié P[au]:

Search results

Items: 1 to 50 of 225

1.

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.

Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrié P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M.

Hepatology. 2007 Jul;46(1):122-9.

PMID:
17526015
2.

The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.

Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Péleraux A, Pénarier G, Soubrié P, Le Fur G, Galiègue S, Casellas P.

FASEB J. 2005 Sep;19(11):1567-9. Epub 2005 Jul 11.

PMID:
16009704
3.

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.

Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vigé X, Biton B, Steinberg R, Françon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrié P, Scatton B.

Neuropsychopharmacology. 2005 Nov;30(11):1963-85.

4.

Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.

Griebel G, Stemmelin J, Gal CS, Soubrié P.

Curr Pharm Des. 2005;11(12):1549-59. Review.

PMID:
15892661
5.
7.

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.

Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O, Soubrié P, Le Fur G.

J Pharmacol Exp Ther. 2004 Sep;310(3):905-14. Epub 2004 May 6.

PMID:
15131245
8.
9.

Specific involvement of neurotensin type 1 receptor in the neurotensin-mediated in vivo dopamine efflux using knock-out mice.

Leonetti M, Brun P, Clerget M, Steinberg R, Soubrié P, Renaud B, Suaud-Chagny MF.

J Neurochem. 2004 Apr;89(1):1-6.

10.

CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.

Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrié P.

Int J Obes Relat Metab Disord. 2004 Apr;28(4):640-8.

PMID:
14770190
11.

SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization.

Gougat J, Ferrari B, Sarran L, Planchenault C, Poncelet M, Maruani J, Alonso R, Cudennec A, Croci T, Guagnini F, Urban-Szabo K, Martinolle JP, Soubrié P, Finance O, Le Fur G.

J Pharmacol Exp Ther. 2004 May;309(2):661-9. Epub 2004 Jan 27.

PMID:
14747609
12.

Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.

Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrié P.

Mol Psychiatry. 2004 Mar;9(3):278-86, 224.

PMID:
14699428
13.

Altered neurotensin mrna expression in mice lacking the dopamine transporter.

Roubert C, Spielewoy C, Soubrié P, Hamon M, Giros B, Betancur C.

Neuroscience. 2004;123(2):537-46.

14.
16.

SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.

Claustre Y, Peretti DD, Brun P, Gueudet C, Allouard N, Alonso R, Lourdelet J, Oblin A, Damoiseau G, Françon D, Suaud-Chagny MF, Steinberg R, Sevrin M, Schoemaker H, George P, Soubrié P, Scatton B.

Neuropsychopharmacology. 2003 Dec;28(12):2064-76.

17.

SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.

Depoortere R, Boulay D, Perrault G, Bergis O, Decobert M, Françon D, Jung M, Simiand J, Soubrié P, Scatton B.

Neuropsychopharmacology. 2003 Nov;28(11):1889-902.

18.

Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice.

Poncelet M, Maruani J, Calassi R, Soubrié P.

Neurosci Lett. 2003 Jun 12;343(3):216-8.

PMID:
12770700
19.

Control by tachykinin NK(2) receptors of CRF(1) receptor-mediated activation of hippocampal acetylcholine release in the rat and guinea-pig.

Desvignes C, Rouquier L, Souilhac J, Mons G, Rodier D, Soubrié P, Steinberg R.

Neuropeptides. 2003 Apr;37(2):89-97.

PMID:
12747940
20.

SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.

Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Leonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrie P, Scatton B.

J Pharmacol Exp Ther. 2003 Jul;306(1):407-20. Epub 2003 Apr 7.

PMID:
12682217
21.

Direct and indirect interactions between cannabinoid CB1 receptor and group II metabotropic glutamate receptor signalling in layer V pyramidal neurons from the rat prefrontal cortex.

Barbara JG, Auclair N, Roisin MP, Otani S, Valjent E, Caboche J, Soubrie P, Crepel F.

Eur J Neurosci. 2003 Mar;17(5):981-90.

PMID:
12653974
22.

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrié P.

Mol Pharmacol. 2003 Apr;63(4):908-14.

PMID:
12644592
23.

Neurotensin enhances glutamate excitotoxicity in mesencephalic neurons in primary culture.

Antonelli T, Tomasini MC, Finetti S, Giardino L, Calzà L, Fuxe K, Soubriè P, Tanganelli S, Ferraro L.

J Neurosci Res. 2002 Dec 15;70(6):766-73.

PMID:
12444598
24.
25.

SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.

Emonds-Alt X, Proietto V, Steinberg R, Oury-Donat F, Vigé X, Vilain P, Naline E, Daoui S, Advenier C, Le Fur G, Maffrand JP, Soubrié P, Pascal M.

J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9.

PMID:
12438541
26.

Expression profile and up-regulation of PRAX-1 mRNA by antidepressant treatment in the rat brain.

Chardenot P, Roubert C, Galiègue S, Casellas P, Le Fur G, Soubrié P, Oury-Donat F.

Mol Pharmacol. 2002 Dec;62(6):1314-20.

PMID:
12435798
27.

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P.

Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R345-53. Epub 2002 Oct 24.

28.

SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.

Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P.

Behav Pharmacol. 2002 Sep;13(5-6):451-63.

PMID:
12394421
29.

Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia.

Remaury A, Vita N, Gendreau S, Jung M, Arnone M, Poncelet M, Culouscou JM, Le Fur G, Soubrié P, Caput D, Shire D, Kopf M, Ferrara P.

Brain Res. 2002 Oct 25;953(1-2):63-72.

PMID:
12384239
30.

SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.

Moser PC, Bergis OE, Jegham S, Lochead A, Duconseille E, Terranova JP, Caille D, Berque-Bestel I, Lezoualc'h F, Fischmeister R, Dumuis A, Bockaert J, George P, Soubrié P, Scatton B.

J Pharmacol Exp Ther. 2002 Aug;302(2):731-41.

PMID:
12130738
31.

The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area.

Leonetti M, Brun P, Sotty F, Steinberg R, Soubrié P, Bert L, Renaud B, Suaud-Chagny MF.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Jun;365(6):427-33. Epub 2002 Apr 26.

PMID:
12070755
32.

Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist.

Emonds-Alt X, Proietto V, Steinberg R, Advenier C, Daoui S, Naline E, Gueudet C, Michaud JC, Oury-Donat F, Poncelet M, Vilain P, Le Fur G, Maffrand JP, Soubrié P, Pascal M.

Can J Physiol Pharmacol. 2002 May;80(5):482-8.

PMID:
12056557
33.

SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair.

Ferzaz B, Brault E, Bourliaud G, Robert JP, Poughon G, Claustre Y, Marguet F, Liere P, Schumacher M, Nowicki JP, Fournier J, Marabout B, Sevrin M, George P, Soubrie P, Benavides J, Scatton B.

J Pharmacol Exp Ther. 2002 Jun;301(3):1067-78.

PMID:
12023539
34.

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P.

Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5. Epub 2002 Apr 16.

36.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J, Guitard J, Gout G, Steinberg R, Rodier D, Griebel G, Soubrie P, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Apr;301(1):322-32.

PMID:
11907190
38.

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.

PMID:
11861823
39.

Activity of SR141716 on post-reinforcement pauses in operant responding for sucrose reward in rats.

Pério A, Barnouin MC, Poncelet M, Soubrié P.

Behav Pharmacol. 2001 Dec;12(8):641-5.

PMID:
11856902
40.

Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery.

Griebel G, Moindrot N, Aliaga C, Simiand J, Soubrié P.

Neurosci Biobehav Rev. 2001 Dec;25(7-8):619-26. Review.

PMID:
11801287
41.

Permissive role of neurokinin NK(3) receptors in NK(1) receptor-mediated activation of the locus coeruleus revealed by SR 142801.

Bert L, Rodier D, Bougault I, Allouard N, Le-Fur G, Soubrié P, Steinberg R.

Synapse. 2002 Jan;43(1):62-9.

PMID:
11746734
42.

Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents.

Griebel G, Perrault G, Soubrié P.

Psychopharmacology (Berl). 2001 Nov;158(3):241-51.

PMID:
11713613
43.

SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats.

Deroche-Gamonet V, Le Moal M, Piazza PV, Soubrié P.

Psychopharmacology (Berl). 2001 Sep;157(3):254-9.

PMID:
11605080
44.

Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function.

Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, Poncelet M, Gueudet C, Desvignes C, Le Fur G, Soubrié P.

J Pharmacol Exp Ther. 2001 Nov;299(2):449-58.

PMID:
11602654
45.

Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration.

Lallemand F, Soubrié PH, De Witte PH.

Alcohol Clin Exp Res. 2001 Sep;25(9):1317-23.

PMID:
11584151
46.

Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist.

Brun P, Leonetti M, Sotty F, Steinberg R, Soubrié P, Renaud B, Suaud-Chagny MF.

J Neurochem. 2001 Jun;77(6):1542-52.

47.

Expression of tachykinin NK2 receptor mRNA in human brain.

Bensaid M, Faucheux BA, Hirsch E, Agid Y, Soubrié P, Oury-Donat F.

Neurosci Lett. 2001 Apr 27;303(1):25-8.

PMID:
11297815
48.
49.
50.

Effects of neurotensin receptor antagonists on the firing rate of rat ventral pallidum neurons.

Michaud JC, Gueudet C, Soubrié P.

Neuroreport. 2000 May 15;11(7):1437-41.

PMID:
10841353

Supplemental Content

Loading ...
Support Center